Evolution of hemangioma endothelium

Kleiman, Alexandra; Keats, Emily C.; Chan, Nancy; Khan, Zia A.

doi:10.1016/j.yexmp.2012.04.020

Cited by 39 publications

(47 citation statements)

References 74 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the involuting phase, the population of endothelial cells begins to decrease. This is followed by the involuted phase, in which endothelial cells are almost not present and the tumor is replaced by fatty tissue with only a minor scar remaining [8].…”

Section: Introductionmentioning

confidence: 99%

Role of pigment epithelium-derived factor in the involution of hemangioma: Autocrine growth inhibition of hemangioma-derived endothelial cells

Kim

Yun

Heo

et al. 2014

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Role of pigment epithelium-derived factor in the involution of hemangioma: Autocrine growth inhibition of hemangioma-derived endothelial cells

Kim

Yun

Heo

et al. 2014

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…10 In the following involuting phase, the differentiation process continues as hemangioma-initiating cells differentiate into ECs and pericytes. 13,14 This involuting phase, like the proliferating phase, is a continuum of cellular and molecular changes with the end result being appearance of adipocytes and fibrofatty residuum. 7,8,14 Most IHs resolve spontaneously and do not require treatment.…”

Section: Infantile Hemangiomamentioning

confidence: 99%

“…13,14 This involuting phase, like the proliferating phase, is a continuum of cellular and molecular changes with the end result being appearance of adipocytes and fibrofatty residuum. 7,8,14 Most IHs resolve spontaneously and do not require treatment. 15 However, therapeutic intervention is necessary in cases where the lesion grows in certain locations and to sizes that could result in life-threatening complications.…”

Section: Infantile Hemangiomamentioning

confidence: 99%

“…57 Interestingly, immunostaining of IH specimens shows co-labeling of EC markers and stem cell markers indicative of an immature EC phenotype in IH. 14,50 Since IHs regrow in a significant proportion of patients that discontinue propranolol treatment, 26 it is possible that hemSCs, unlike hemECs and normal vascular ECs, are not susceptible to propranolol-induced apoptosis. This may explain why recurrence of these tumors often occurs following cessation of treatment.…”

Section: Hemangioma-derived Stem Cells (Hemscs)mentioning

confidence: 99%

See 1 more Smart Citation

Mechanisms of propranolol action in infantile hemangioma

Kum

Khan

2014

Dermato-Endocrinology

View full text Add to dashboard Cite

“…According to the life span, HAs are divided into proliferating phase (rapid growth) and involuting phase HAs (spontaneous regression) [2]. The somatic mutations, such as von Hippel-Lindau (VHL) contribute to the development of HAs [3].…”

Section: Introductionmentioning

confidence: 99%

lncRNA MEG3 Suppresses the Tumorigenesis of Hemangioma by Sponging miR-494 and Regulating PTEN/ PI3K/AKT Pathway

Dai

Wan

Qiu

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Dysregulation of long noncoding RNAs (lncRNAs) is associated with the proliferation and metastasis in a variety of cancers, of which lncRNA maternally expressed gene 3 (MEG3) has been indicated as a tumor suppressor in multiple malignancies. However, the underlying mechanisms by which MEG3 contributes to human hemangiomas (HAs) remain undetermined. Methods: qRT-PCR analysis was performed to examine the expression levels of MEG3 and VEGF in proliferating or involuting phase HAs. MTT, colony formation assay, flow cytometry analysis and a subcutaneous xenograft tumor model were conducted to assess the effects of MEG3 on the HAs tumorigenesis. The interaction between MEG3 and miRNAs or their downstream pathways was evidenced by bioinformatic analysis, luciferase report assays, RNA immunoprecipitation (RIP) assay. and Western blot analysis. Results: The expression of MEG3 was substantially decreased and had a negative correlation with VEGF expression in proliferating phase HAs, as compared with the involuting phase HAs and normal skin tissues. Ectopic expression of MEG3 suppressed cell proliferation, colony formation and induced cycle arrest in vitro and in vivo, followed by the downregulation of VEGF and cyclinD1, but knockdown of MEG3 reversed these effects. Furthermore, MEG3 was verified to act as a sponge of miR-494 in HAs cells, and miR-494 counteracted MEG3-caused anti-proliferative effects by regulating PTEN/PI3K/AKT pathway, and exhibited the negative correlation with MEG3 and PTEN expression in proliferating phase HAs. Conclusion: Our findings suggested that lncRNA MEG3 inhibited HAs tumorigenesis by sponging miR-494 and regulating PTEN/PI3K/AKT pathway.

show abstract

Evolution of hemangioma endothelium

Cited by 39 publications

References 74 publications

Role of pigment epithelium-derived factor in the involution of hemangioma: Autocrine growth inhibition of hemangioma-derived endothelial cells

Role of pigment epithelium-derived factor in the involution of hemangioma: Autocrine growth inhibition of hemangioma-derived endothelial cells

Mechanisms of propranolol action in infantile hemangioma

lncRNA MEG3 Suppresses the Tumorigenesis of Hemangioma by Sponging miR-494 and Regulating PTEN/ PI3K/AKT Pathway

Contact Info

Product

Resources

About